Healthcare AI startup Triomics has secured $22 million in Series B funding to expand its platform that automates cancer care workflows using artificial intelligence. The round was led by Polaris Partners, with participation from existing investors including Venrock and Om drop Capital.
Triomics’ AI-powered platform helps oncology practices streamline critical tasks like tumor board preparation, cancer registry reporting, and clinical trial matching. Currently, cancer care teams spend hours manually gathering patient data, reviewing pathology reports, and entering information into multiple systems. Triomics’ automation reduces this workload significantly, allowing doctors to focus more on patient care rather than administrative tasks.
The company’s platform uses natural language processing (NLP) and machine learning to extract relevant data from medical records, pathology reports, and imaging studies automatically. This data is then organized into structured formats that support clinical decision-making and regulatory compliance.
With the new $22 million funding, Triomics plans to expand its engineering team, accelerate product development, and grow its sales efforts across North America. The company currently serves over 100 oncology practices and community cancer centers, processing thousands of patient cases monthly.
The oncology automation market is growing rapidly as cancer diagnoses increase globally and healthcare systems face staffing shortages. Triomics’ solution addresses a critical pain point: oncologists spend up to 35% of their time on administrative work instead of treating patients. By automating these workflows, Triomics helps practices improve efficiency, reduce errors, and accelerate treatment decisions.
FAQs [Frequently Asked Questions]
Q1: How much funding did Triomics raise and who led the round?
Triomics raised $22 million in Series B funding, led by Polaris Partners with participation from Venrock and Omicide Capital.
Q2: What does Triomics’ AI platform automate in oncology care?
It automates tumor board preparation, cancer registry reporting, and clinical trial matching using natural language processing and machine learning.
Q3: How many oncology practices currently use Triomics’ platform?
Triomics serves over 100 oncology practices and community cancer centers, processing thousands of patient cases every month.